{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:20:19Z","timestamp":1770988819517,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Malaria caused by<jats:italic>Plasmodium falciparum<\/jats:italic>in pregnancy can result in adverse maternal and fetal sequelae. This review evaluated the adherence of the national guidelines drawn from World Health Organization (WHO) regions, Africa, Eastern Mediterranean, Southeast Asia, and Western Pacific, to the WHO recommendations on drug treatment and prevention of chloroquine-resistant falciparum malaria in pregnant women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty-five updated national guidelines and the President\u2019s Malaria Initiative (PMI), available in English language, were reviewed. The primary outcome measures were the first-line anti-malarial treatment protocols adopted by national guidelines for uncomplicated and complicated falciparum malaria infections in early (first) and late (second and third) trimesters of pregnancy. The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This review evaluated the treatment and prevention of falciparum malaria in pregnancy in 35 national guidelines\/PMI-Malaria Operational Plans (MOP) reports out of 95 malaria-endemic countries. Of the 35 national guidelines, 10 (28.6%) recommend oral quinine plus clindamycin as first-line treatment for uncomplicated malaria in the first trimester. As the first-line option, artemether\u2013lumefantrine, an artemisinin-based combination therapy, is adopted by 26 (74.3%) of the guidelines for treating uncomplicated or complicated malaria in the second and third trimesters. Intravenous artesunate is approved by 18 (51.4%) and 31 (88.6%) guidelines for treating complicated malaria during early and late pregnancy, respectively. Of the 23 national guidelines that recommend IPTp-SP strategy, 8 (34.8%) are not explicit about directly observed therapy requirements, and three-quarters, 17 (73.9%), do not specify contra-indication of SP in human immunodeficiency virus (HIV)-infected pregnant women receiving cotrimoxazole prophylaxis. Most of the guidelines (18\/23; 78.3%) state the recommended folic acid dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Several national guidelines and PMI reports require update revisions to harmonize with international guidelines and emergent trends in managing falciparum malaria in pregnancy. National guidelines and those of donor agencies should comply with those of WHO guideline recommendations although local conditions and delayed guideline updates may call for deviations from WHO evidence-based guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12936-020-03565-2","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T08:02:59Z","timestamp":1611388979000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-7686","authenticated-orcid":false,"given":"Khalid A. J.","family":"Al Khaja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reginald P.","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"key":"3565_CR1","unstructured":"WHO. Guidelines for the treatment of malaria. Third edition, 2015. Geneva, World Health Organization, 2015. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/. Accessed 15 Jun 2020."},{"key":"3565_CR2","unstructured":"Population reference bureau (PRB). Malaria Continues to Threaten Pregnant Women and Children. 2001. https:\/\/www.prb.org\/malariacontinuestothreatenpregnantwomenandchildren\/. Accessed 8 Jun 2020."},{"key":"3565_CR3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0035-9203(83)90081-0","volume":"77","author":"IA McGregor","year":"1983","unstructured":"McGregor IA, Wilson ME, Billewicz WZ. Malaria infection of the placenta in The Gambia, West Africa; its incidence and relationship to stillbirth, birthweight and placental weight. Trans R Soc Trop Med Hyg. 1983;77:232\u201344.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3565_CR4","first-page":"169","volume":"295","author":"PE Duffy","year":"2005","unstructured":"Duffy PE, Fried M. Malaria in the pregnant woman. Curr Top Microbiol Immunol. 2005;295:169\u2013200.","journal-title":"Curr Top Microbiol Immunol"},{"key":"3565_CR5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fmed.2017.00117","volume":"25","author":"L Sharma","year":"2017","unstructured":"Sharma L, Shukla G. Placental\u00a0malaria: a new insight into the pathophysiology. Front Med (Lausanne). 2017;25:117.","journal-title":"Front Med (Lausanne)."},{"key":"3565_CR6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1586\/eri.12.123","volume":"10","author":"AL Conroy","year":"2012","unstructured":"Conroy AL, McDonald CR, Kain KC. Malaria in pregnancy: diagnosing infection and identifying fetal risk. Expert Rev Anti Infect Ther. 2012;10:1331\u201342.","journal-title":"Expert Rev Anti Infect Ther."},{"key":"3565_CR7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1586\/eri.12.98","volume":"10","author":"M Fried","year":"2012","unstructured":"Fried M, Muehlenbachs A, Duffy PE. Diagnosing malaria in pregnancy: an update. Expert Rev Anti Infect Ther. 2012;10:1177\u201387.","journal-title":"Expert Rev Anti Infect Ther."},{"key":"3565_CR8","unstructured":"WHO. Policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). Geneva, World Health Organization, 2013. https:\/\/www.who.int\/malaria\/publications\/atoz\/policy_brief_iptp_sp_policy_recommendation\/en\/. Accessed 15 Jun 2020."},{"key":"3565_CR9","unstructured":"WHO. Malaria: intermittent preventive treatment in pregnancy (IPTp). Last update: 21 October 2019. Geneva, World Health Organization. https:\/\/www.who.int\/malaria\/areas\/preventive_therapies\/pregnancy\/en\/. Accessed 8 Jun 2020."},{"key":"3565_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/0035-9203(91)90205-D","volume":"85","author":"F Nosten","year":"1991","unstructured":"Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ. Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg. 1991;85:424\u20139.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3565_CR11","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1128\/AAC.02595-14","volume":"58","author":"D Mosha","year":"2014","unstructured":"Mosha D, Guidi M, Mwingira F, Abdulla S, Mercier T, Decosterd LA, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58:4583\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"3565_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1473-3099(11)70315-2","volume":"12","author":"MJ Rijken","year":"2012","unstructured":"Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis. 2012;12:75\u201388.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR13","unstructured":"Herchline TE, Bronze MS. Malaria: Practice essentials, background, etiology. Medscape reference. https:\/\/emedicine.medscape.com\/article\/221134-overview. Accessed 4 Jun 2020."},{"key":"3565_CR14","unstructured":"WHO. Guidelines for the treatment of malaria,\u00a02nd\u00a0Edn. Geneva, World Health Organization,\u00a02010. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK254223\/. Accessed 5 Jun 2020."},{"key":"3565_CR15","unstructured":"WHO. World malaria report 2019. Geneva, World Health Organization, 2019. https:\/\/www.who.int\/publications-detail\/world-malaria-report-2019. Accessed 8 Jun 2020."},{"key":"3565_CR16","unstructured":"Center for disease control and prevention (CDC). President\u2019s Malaria Initiative (PMI). https:\/\/www.cdc.gov\/malaria\/malaria_worldwide\/cdc_activities\/pmi.html. Accessed 8 Jun 2020."},{"key":"3565_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/14740338.2018.1535593","volume":"17","author":"M Saito","year":"2018","unstructured":"Saito M, Gilder ME, McGready R, Nosten F. Antimalarial drugs for treating and preventing malaria in pregnant and lactating women. Expert Opin Drug Saf. 2018;17:1129\u201344.","journal-title":"Expert Opin Drug Saf."},{"key":"3565_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1475-2875-10-144","volume":"10","author":"J Achan","year":"2011","unstructured":"Achan J, Talisuna AO, Erhart A, Yeka A, Tibenderana JK, Baliraine FN, et al. Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J. 2011;10:144.","journal-title":"Malar J."},{"key":"3565_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF00315138","volume":"40","author":"W Supanaranond","year":"1991","unstructured":"Supanaranond W, Davis TM, Pukrittayakamee S, Silamut K, Karbwang J, Molunto P, et al. Disposition of oral quinine in acute falciparum malaria. Eur J Clin Pharmacol. 1991;40:49\u201352.","journal-title":"Eur J Clin Pharmacol"},{"key":"3565_CR20","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1128\/AAC.00683-13","volume":"57","author":"J Tarning","year":"2013","unstructured":"Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, et al. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Antimicrob Agents Chemother. 2013;57:5096\u2013103.","journal-title":"Antimicrob Agents Chemother"},{"key":"3565_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12936-017-2135-y","volume":"16","author":"M Saito","year":"2017","unstructured":"Saito M, Gilder ME, Nosten F, McGready R, Gu\u00e9rin PJ. Systematic literature review and meta-analysis of the efficacy of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: methodological challenges. Malar J. 2017;16:488.","journal-title":"Malar J."},{"key":"3565_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0035-9203(01)90106-3","volume":"95","author":"R McGready","year":"2001","unstructured":"McGready R, Cho T, Villegas L, Brockman A, van Vugt M, et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2001;95:651\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3565_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2875-11-2","volume":"11","author":"CO Obonyo","year":"2012","unstructured":"Obonyo CO, Juma EA. Clindamycin plus quinine for treating uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J. 2012;11:2.","journal-title":"Malar J."},{"key":"3565_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S1473-3099(09)70109-4","volume":"9","author":"A Yeka","year":"2009","unstructured":"Yeka A, Achan J, D\u2019Alessandro U, Talisuna AO. Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? Lancet Infect Dis. 2009;9:448\u201352.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1473-3099(10)70202-4","volume":"10","author":"P Piola","year":"2010","unstructured":"Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2010;10:762\u20139.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR26","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1128\/AAC.44.9.2395-2398.2000","volume":"44","author":"S Pukrittayakamee","year":"2000","unstructured":"Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 2000;44:2395\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3565_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4269\/ajtmh.2005.73.263","volume":"73","author":"AA Adegnika","year":"2005","unstructured":"Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Sch\u00fctte D, Oyakhirome S, et al. Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambar\u00e9n\u00e9, Gabon. Am J Trop Med Hyg. 2005;73:263\u20136.","journal-title":"Am J Trop Med Hyg."},{"key":"3565_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40264-014-0261-9","volume":"38","author":"Stephanie D Kovacs","year":"2015","unstructured":"Kovacs Stephanie D, Rijken Marcus J, Stergachis Andy. Treating severe malaria in pregnancy: a review of the evidence. Drug Saf. 2015;38:165\u201381.","journal-title":"Drug Saf"},{"key":"3565_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0035-9203(93)90139-H","volume":"87","author":"F Nosten","year":"1993","unstructured":"Nosten F, ter Kuile F, Thwai KL, Maelankirri L, White NJ. Spiramycin does not potentiate quinine treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 1993;87:305\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3565_CR30","unstructured":"Management Sciences for Health (MSH)\/WHO. International Medical Products Price Guide. 2015 edition. https:\/\/www.msh.org\/sites\/default\/files\/msh-2015-international-medical-products-price-guide.pdf. Accessed 7 Jun 2020."},{"key":"3565_CR31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12936-016-1169-x","volume":"15","author":"WHO Malaria Policy Advisory Committee and Secretariat","year":"2016","unstructured":"WHO Malaria Policy Advisory Committee and Secretariat. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015). Malar J. 2016;15:117.","journal-title":"Malar J."},{"key":"3565_CR32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1473-3099(20)30064-5","volume":"20","author":"M Saito","year":"2020","unstructured":"Saito M, Mansoor R, Kennon K, Anvikar AR, Ashley EA, Chandramohan D, et al. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2020;20:943\u201352.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1473-3099(15)00547-2","volume":"16","author":"KA Moore","year":"2016","unstructured":"Moore KA, Simpson JA, Paw MK, Pimanpanarak M, Wiladphaingern J, Rijken MJ, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis. 2016;16:576\u201383.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12936-015-0578-6","volume":"14","author":"C Manyando","year":"2015","unstructured":"Manyando C, Njunju EM, Virtanen M, Hamed K, Gomes M, Van Geertruyden JP. Exposure to artemether-lumefantrine (Coartem) in first trimester pregnancy in an observational study in Zambia. Malar J. 2015;14:77.","journal-title":"Malar J."},{"key":"3565_CR35","doi-asserted-by":"crossref","first-page":"e1002290","DOI":"10.1371\/journal.pmed.1002290","volume":"14","author":"S Dellicour","year":"2017","unstructured":"Dellicour S, Sevene E, McGready R, Tinto H, Mosha D, Manyando C, et al. First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLoS Med. 2017;14:e1002290.","journal-title":"PLoS Med."},{"key":"3565_CR36","first-page":"424","volume":"67","author":"SB Ballard","year":"2018","unstructured":"Ballard SB, Salinger A, Arguin PM, Desai M, Tan KR. Updated CDC recommendations for using artemether-lumefantrine for the treatment of uncomplicated malaria in pregnant women in the United States. MMWR. 2018;67:424\u201331.","journal-title":"MMWR."},{"key":"3565_CR37","unstructured":"WHO. Assessment of the safety of artemisinin compounds in pregnancy. Report of two joint informal consultations convened. Geneva, World Health Organization, 2006. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/43797\/9789241596114_eng.pdf;jsessionid=C1B9576EAE5B24BB942FA133F84C1309?sequence=1. Accessed 8 Jun 2020."},{"key":"3565_CR38","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/S1473-3099(18)30065-3","volume":"18","author":"U D\u2019Alessandro","year":"2018","unstructured":"D\u2019Alessandro U, Hill J, Tarning J, Pell C, Webster J, Gutman J, et al. Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infect Dis. 2018;18:e133\u201346.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/ofid\/ofv170","volume":"3","author":"RJ Burger","year":"2015","unstructured":"Burger RJ, van Eijk AM, Bussink M, Hill J, Ter Kuile FO. Artemisinin-based combination therapy versus quinine or other combinations for treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2015;3:170.","journal-title":"Open Forum Infect Dis."},{"key":"3565_CR40","doi-asserted-by":"publisher","first-page":"e0164963","DOI":"10.1371\/journal.pone.0164963","volume":"11","author":"SD Kovacs","year":"2016","unstructured":"Kovacs SD, van Eijk AM, Sevene E, Sevene E, Dellicour S, Weiss NS, et al. The safety of artemisinin derivatives for the treatment of malaria in the 2nd or 3rd trimester of pregnancy: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0164963.","journal-title":"PLoS ONE"},{"key":"3565_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12916-020-01592-z","volume":"18","author":"M Saito","year":"2020","unstructured":"Saito M, Mansoor R, Kennon K, Anvikar AR, Ashley EA, Chandramohan D, et al. Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Med. 2020;18:138.","journal-title":"BMC Med."},{"key":"3565_CR42","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1508606","volume":"374","author":"The PREGACT Study Group","year":"2016","unstructured":"The PREGACT Study Group. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016;374:913\u201327.","journal-title":"N Engl J Med"},{"key":"3565_CR43","unstructured":"Public Health England. Guidelines for malaria prevention in travellers from the UK 2019. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/833506\/ACMP_Guidelines.pdf. Accessed 9 Jun 2020."},{"key":"3565_CR44","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/1475-2875-11-328","volume":"11","author":"HH Askling","year":"2012","unstructured":"Askling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, et al. Management of imported malaria in Europe. Malar J. 2012;11:328.","journal-title":"Malar J."},{"key":"3565_CR45","unstructured":"Ministry of Health, Saudi Arabia. National Malaria Drug Policy. 3rd edition 2018. https:\/\/www.moh.gov.sa\/Ministry\/About\/Health%20Policies\/029.pdf. Accessed 8 Jun 2020."},{"key":"3565_CR46","unstructured":"Department of Health, Republic of South Africa. National Guidelines for the Treatment of Malaria, South Africa 2019. https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2017\/03\/National-Guidelines-for-Malaria-Treatment-SEPTEMBER-2019-Update-WITH-FRONT.pdf. Accessed 8 Jun 2020."},{"key":"3565_CR47","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1517\/14656566.2013.771167","volume":"14","author":"B Ogutu","year":"2013","unstructured":"Ogutu B. Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Expert Opin Pharmacother. 2013;14:643\u201354.","journal-title":"Expert Opin Pharmacother"},{"key":"3565_CR48","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","volume":"395","author":"RW van der Pluijm","year":"2020","unstructured":"van der Pluijm RW, Tripura R, Hoglund RM, Phyo AP, Lek D, Islam A, et al. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020;395:1345\u201360.","journal-title":"Lancet"},{"key":"3565_CR49","doi-asserted-by":"crossref","first-page":"e01140","DOI":"10.1128\/AAC.01140-19","volume":"64","author":"MA Onyamboko","year":"2020","unstructured":"Onyamboko MA, Hoglund RM, Lee SJ, Kabedi C, Kayembe D, Badjanga BB, et al. A randomised controlled trial of 3 versus 5\u00a0days artemether-lumefantrine regimen for uncomplicated Plasmodium falciparum treatment in pregnancy in Africa. Antimicrob Agents Chemother. 2020;64:e01140.","journal-title":"Antimicrob Agents Chemother"},{"key":"3565_CR50","doi-asserted-by":"publisher","first-page":"e1002579","DOI":"10.1371\/journal.pmed.1002579","volume":"15","author":"F Kloprogge","year":"2018","unstructured":"Kloprogge F, Workman L, Borrmann S, T\u00e9k\u00e9t\u00e9 M, Lef\u00e8vre G, Hamed K, et al. Artemether\u2013lumefantrine dosing for malaria treatment in young children and pregnant women: a pharmacokinetic-pharmacodynamic meta-analysis. PLoS Med. 2018;15:e1002579.","journal-title":"PLoS Med."},{"key":"3565_CR51","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12936-018-2404-4","volume":"17","author":"KM Tun","year":"2018","unstructured":"Tun KM, Jeeyapant A, Myint AH, Kyaw ZT, Dhorda M, Mukaka M, et al. Effectiveness and safety of 3 and 5\u00a0day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malar J. 2018;17:258.","journal-title":"Malar J."},{"key":"3565_CR52","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00044011-199918060-00006","volume":"18","author":"G Lef\u00e8vre","year":"2012","unstructured":"Lef\u00e8vre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet\u00ae). Clin Drug Invest. 2012;18:467\u201380.","journal-title":"Clin Drug Invest."},{"key":"3565_CR53","unstructured":"WHO. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. Informal consultation organized by the world health organization with the technical support of the worldwide antimalarial resistance network. 22\u201324 February, 2010 Bangkok, Thailand. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44653\/9789241502061_eng.pdf?sequence=1&isAllowed=y. Accessed 3 Jun 2020."},{"key":"3565_CR54","unstructured":"PMI. President\u2019s Malaria Initiative: Fight malaria and saving life. Resource library FY 2019. https:\/\/www.pmi.gov\/resource-library\/mops\/fy-2019. Accessed 8 Jun 2020."},{"key":"3565_CR55","unstructured":"General Circular No: 02-112\/2014. Department of Health Services, Colombo. Guidelines on malaria chemotherapy and management of patients with malaria. http:\/\/amc.health.gov.lk\/Circulars\/Treatment-guidelines_Malaria.pdf. Accessed 11 Jun 2020."},{"key":"3565_CR56","unstructured":"CDC. Guidelines for treatment of malaria in the United States, 2019. https:\/\/www.cdc.gov\/malaria\/diagnosis_treatment\/index.html. Accessed 15 Jun 2020."},{"key":"3565_CR57","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1128\/AAC.48.4.1329-1334.2004","volume":"48","author":"S Pukrittayakamee","year":"2004","unstructured":"Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother. 2004;48:1329\u201334.","journal-title":"Antimicrob Agents Chemother"},{"key":"3565_CR58","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1473-3099(11)70339-5","volume":"12","author":"R McGready","year":"2012","unstructured":"McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388\u201396.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR59","unstructured":"Republic of Sudan, Federal Ministry of Health. Sudan Malaria Diagnosis and Treatment Protocol 2017. https:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/sudan_malaria_treatment_protocol_final.21_nov_docx.pdf. Accessed 10 Jun 2020."},{"key":"3565_CR60","unstructured":"Guidelines for the Diagnosis and Treatment of Malaria in Somalia 2016. https:\/\/www.humanitarianresponse.info\/sites\/www.humanitarianresponse.info\/files\/documents\/files\/malaria_diagnosis_and_treatment_guidelines_180316.pdf. Accessed 8 Jun 2020."},{"key":"3565_CR61","first-page":"9278432","volume":"1","author":"S Amankwah","year":"2019","unstructured":"Amankwah S, Anto F. Factors associated with uptake of intermittent preventive treatment of malaria in pregnancy: a crosss-sectional study in private health facilities in Tema metropolis, Ghana. J Trop Med. 2019;1:9278432.","journal-title":"J Trop Med."},{"key":"3565_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00002018-200730060-00003","volume":"30","author":"PJ Peters","year":"2007","unstructured":"Peters PJ, Thigpen MC, Parise ME, Newman RD. Safety and toxicity of sulfadoxine\/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007;30:481\u2013501.","journal-title":"Drug Saf"},{"key":"3565_CR63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1046\/j.1365-3156.1999.00349.x","volume":"4","author":"FH Verhoeff","year":"1999","unstructured":"Verhoeff FH, Brabin BJ, Hart CA, Chimsuku L, Kazembe P, Broadhead RL. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop Med Int Health. 1999;4:5\u201312.","journal-title":"Trop Med Int Health."},{"key":"3565_CR64","first-page":"123","volume":"9","author":"TE Kwenti","year":"2018","unstructured":"Kwenti TE. Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies. Res Rep Trop Med. 2018;9:123\u201336.","journal-title":"Res Rep Trop Med."},{"key":"3565_CR65","unstructured":"WHO. Malaria in HIV\/AIDS patients. Last update: 27 April 2017. https:\/\/www.who.int\/malaria\/areas\/high_risk_groups\/hiv_aids_patients\/en\/. Accessed 10 Jun 2020."},{"key":"3565_CR66","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1517\/14656561003733599","volume":"11","author":"E Sevene","year":"2010","unstructured":"Sevene E, Gonz\u00e1lez R, Men\u00e9ndez C. Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother. 2010;11:1277\u201393.","journal-title":"Expert Opin Pharmacother"},{"key":"3565_CR67","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(18)30732-1","volume":"19","author":"AM van Eijk","year":"2019","unstructured":"van Eijk AM, Larsen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C, et al. Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:546\u201356.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR68","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/S0140-6736(15)00310-4","volume":"386","author":"M Desai","year":"2015","unstructured":"Desai M, Gutman J, L\u2019lanziva A, Otieno K, Juma E, Kariuki S, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin\u2013piperaquine versus intermittent preventive treatment with sulfadoxine\u2013pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;386:2507\u201319.","journal-title":"Lancet"},{"key":"3565_CR69","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1473-3099(18)30297-4","volume":"18","author":"XHS Chan","year":"2018","unstructured":"Chan XHS, Win YN, Mawer LJ, Tan JY, Brugada J, White NJ. Risk of sudden unexplained death after use of dihydroartemisinin\u2013piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018;18:913\u201323.","journal-title":"Lancet Infect Dis."},{"key":"3565_CR70","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3018(15)00005-3","volume":"2","author":"AB Suthar","year":"2015","unstructured":"Suthar AB, Vitoria MA, Nagata JM, Anglaret X, Mbori-Ngacha D, Sued O, et al. Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. Lancet HIV. 2015;2:e137\u201350.","journal-title":"Lancet HIV."},{"key":"3565_CR71","unstructured":"ISGlobal. Research, maternal, child and reproductive health. HIV-Positive Pregnant Women in Malaria-Endemic Zones: A Vulnerable Population. 2014. https:\/\/www.isglobal.org\/en_GB\/-\/el-riesgo-de-ser-mujer-embarazada-vih-positiva-en-una-zona-de-malaria. Accessed 12 Jun 2020."},{"key":"3565_CR72","unstructured":"Revised (Current) Malaria Treatment Regimen Updated Version 2016- (6th Revision). National malaria control program, Directorate General of Health Services, Ministry of Health & Family Welfare, Dhaka, Bangladesh. http:\/\/www.brac.net\/program\/wp-content\/uploads\/2018\/09\/National-Malaria-Treatment-Regimen-2016.pdf. Accessed 8 Jun 2020."},{"key":"3565_CR73","doi-asserted-by":"crossref","unstructured":"National Institute of Malaria Research New Delhi. Guidelines for Diagnosis and Treatment of Malaria in India 2014. https:\/\/www.researchgate.net\/publication\/327155827_Guidelines_for_diagnosis_and_treatment_of_malaria_in_india. Accessed 4 Jan 2021.","DOI":"10.24321\/2455.7048.202116"},{"key":"3565_CR74","unstructured":"Ministry of Health Malaysia. Management: Guidelines of malaria in Malaysia. https:\/\/www.moh.gov.my\/index.php\/file_manager\/dl_item\/554756755a584a69615852686269394859584a70637942515957356b645746754c31426c626d6431636e567a595734675330567a615768686447467549435967613246335957786862694277655774706443394e515535425230564e52553555583064565355524654456c4f52564e6654305a665455464d51564a4a5156394a546c394e5155784257564e4a515335775a475978587935775a47593d. Accessed 4 Jan 2021."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03565-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12936-020-03565-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03565-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:41:37Z","timestamp":1670892097000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03565-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3565"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03565-2","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There is no competing interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}